Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 121: Drug distribution is influenced by which of the following factors?

A. Plasma protein binding
B. Lipid solubility
C. Degree of blood flow
D. All of these (Correct Answer)

Explanation: **Explanation:** Drug distribution is the reversible transfer of a drug from the systemic circulation to the various organs and tissues of the body. This process is governed by several physicochemical and physiological factors: 1. **Plasma Protein Binding:** Drugs bound to plasma proteins (like albumin for acidic drugs and $\alpha_1$-acid glycoprotein for basic drugs) are trapped in the vascular compartment because the protein-drug complex is too large to cross capillary membranes. Only the **free (unbound) fraction** can distribute into tissues. 2. **Lipid Solubility:** The cell membrane is a lipid bilayer. Highly lipid-soluble (lipophilic) drugs cross biological membranes easily and distribute extensively into tissues, often resulting in a high **Volume of Distribution ($V_d$)**. 3. **Blood Flow (Perfusion):** Distribution occurs more rapidly in highly perfused organs (brain, heart, liver, kidneys) compared to poorly perfused tissues (skeletal muscle, fat, bone). **Why "All of these" is correct:** Since distribution depends on the drug's ability to leave the blood (binding), cross membranes (solubility), and reach the site (blood flow), all three factors are critical determinants. **Clinical Pearls for NEET-PG:** * **Volume of Distribution ($V_d$):** A theoretical volume; drugs with high $V_d$ (e.g., Digoxin, Chloroquine) are sequestered in tissues and cannot be removed by hemodialysis. * **Redistribution:** Highly lipid-soluble drugs (e.g., **Thiopentone**) initially enter the brain but quickly redistribute to less perfused tissues like fat, leading to a short duration of action despite a long half-life. * **Blood-Brain Barrier (BBB):** Only highly lipid-soluble, non-ionized drugs can cross the BBB.

Question 122: What is implied if a drug has more renal clearance than the Glomerular Filtration Rate (GFR)?

A. The drug is reabsorbed in the renal tubules.
B. The drug is secreted in the renal tubules. (Correct Answer)
C. The drug is excreted in bile.
D. The drug is neither secreted nor reabsorbed.

Explanation: ### Explanation The net renal excretion of a drug is the result of three processes: **Glomerular Filtration + Tubular Secretion - Tubular Reabsorption.** **1. Why Option B is Correct:** The Glomerular Filtration Rate (GFR) represents the volume of plasma filtered through the glomeruli per unit of time (normal $\approx$ 125 mL/min). If a drug's renal clearance is **greater than the GFR**, it means that more drug is appearing in the urine than can be accounted for by filtration alone. This additional amount must be added to the tubular fluid via **active tubular secretion** (occurring primarily in the proximal convoluted tubule). **2. Why Other Options are Incorrect:** * **Option A:** If a drug is **reabsorbed**, its renal clearance will be **less than the GFR** (e.g., Glucose has zero clearance because it is 100% reabsorbed). * **Option C:** Biliary excretion refers to drug elimination via feces and does not contribute to the calculation of *renal* clearance. * **Option D:** If a drug is neither secreted nor reabsorbed, its renal clearance will be **equal to the GFR** (e.g., Inulin or Creatinine). ### High-Yield Clinical Pearls for NEET-PG * **Inulin Clearance:** The gold standard for measuring GFR because it is freely filtered but neither secreted nor reabsorbed ($Cl_{renal} = GFR$). * **Para-amino hippuric acid (PAH):** Used to measure **Renal Plasma Flow** because it is both filtered and extensively secreted ($Cl_{renal} > GFR$). * **Competition for Secretion:** Drugs using the same secretory transporters can compete, leading to interactions. *Example:* **Probenecid** inhibits the tubular secretion of **Penicillin**, thereby increasing its half-life and plasma concentration. * **Protein Binding:** Only the unbound (free) fraction of a drug is filtered, but tubular secretion can clear both free and protein-bound drugs.

Question 123: What is the clearance of a drug?

A. The volume of plasma cleared of the drug per unit of time. (Correct Answer)
B. The amount of drug excreted in the urine.
C. The amount of drug metabolized per unit of time.
D. All of the above.

Explanation: **Explanation:** **1. Why Option A is Correct:** Clearance ($CL$) is a fundamental pharmacokinetic parameter defined as the **volume of plasma** from which a drug is completely removed per unit of time (e.g., mL/min or L/hr). It represents the efficiency of drug elimination. The key conceptual takeaway is that clearance refers to the **volume of fluid processed**, not the absolute amount of the drug removed. It is mathematically expressed as: $$CL = \frac{\text{Rate of elimination}}{\text{Plasma concentration (C)}}$$ **2. Why Other Options are Incorrect:** * **Option B:** This describes **renal excretion**, which is only one component of total body clearance. Clearance also includes hepatic metabolism and biliary excretion. Furthermore, "amount" refers to mass (mg), whereas clearance is a volume-based rate. * **Option C:** This describes the **Rate of Elimination**. While clearance and rate of elimination are related, they are not identical. In first-order kinetics, the rate of elimination changes as the drug concentration falls, but the **clearance remains constant**. **3. NEET-PG High-Yield Clinical Pearls:** * **Total Body Clearance ($CL_{total}$):** Sum of $CL_{renal} + CL_{hepatic} + CL_{other}$. * **First-order vs. Zero-order:** For most drugs (first-order), clearance is constant. For drugs like Phenytoin, Ethanol, and Aspirin (zero-order/saturation kinetics), clearance decreases as the plasma concentration increases. * **Maintenance Dose (MD):** Clearance is the primary determinant for calculating the MD. * $MD = \text{Target } C_{ss} \times CL$ * **Half-life ($t_{1/2}$):** Clearance is inversely proportional to half-life ($t_{1/2} = 0.693 \times V_d / CL$). If clearance decreases (e.g., renal failure), the half-life increases.

Question 124: Which of the following is NOT true for the sublingual route of drug administration?

A. It allows drugs to bypass first-pass metabolism.
B. All drugs can be administered via this route. (Correct Answer)
C. The action of the drug can be terminated at any time.
D. It provides rapid absorption of the drug.

Explanation: ### Explanation The sublingual route involves placing a drug under the tongue, where it dissolves and is absorbed through the rich capillary network of the oral mucosa directly into the systemic circulation. **Why Option B is the Correct Answer (The False Statement):** Not all drugs can be administered sublingually. To be effective via this route, a drug must be **lipid-soluble, non-irritating, and potent** (effective in small doses). Large, water-soluble molecules or drugs with an unpleasant taste are unsuitable. Furthermore, if a drug requires a very high dose, the limited surface area of the sublingual mucosa cannot accommodate it. **Analysis of Other Options:** * **Option A (Bypasses first-pass metabolism):** This is **true**. Venous drainage from the mouth goes directly into the superior vena cava, bypassing the portal circulation and the liver. This increases the bioavailability of drugs like Nitroglycerin. * **Option C (Termination of action):** This is **true**. If side effects occur or the desired effect is reached, the patient can simply spit out the remaining tablet, stopping further absorption. * **Option D (Rapid absorption):** This is **true**. Due to the high vascularity of the sublingual mucosa, drugs reach the bloodstream quickly, making this route ideal for emergencies (e.g., angina). **NEET-PG High-Yield Pearls:** * **Classic Example:** **Nitroglycerin (GTN)** is the prototype for sublingual administration in acute angina. * **Other Drugs:** Buprenorphine, Desmopressin, and Nifedipine (though oral/bite-and-swallow is now preferred for Nifedipine due to safety). * **Key Advantage:** Avoids destruction by gastric acid and digestive enzymes (e.g., why certain peptides are explored for this route). * **Key Disadvantage:** It can cause irritation of the oral mucosa and is inconvenient for frequent dosing.

Question 125: Which of the following compounds does not cross the blood-brain barrier?

A. Pralidoxime (Correct Answer)
B. Obidoxime
C. Diacetyl monoxime
D. Physostigmine

Explanation: ### Explanation The ability of a drug to cross the **Blood-Brain Barrier (BBB)** is primarily determined by its lipid solubility and ionization state. Compounds that are highly ionized (polar) or possess a quaternary ammonium structure generally cannot penetrate the central nervous system (CNS). **1. Why Pralidoxime is the Correct Answer:** **Pralidoxime (2-PAM)** is a **quaternary ammonium compound**. Due to its permanent positive charge, it is highly polar and lipid-insoluble. Consequently, it **does not cross the BBB** and can only reactivate acetylcholinesterase (AChE) at the neuromuscular junction and peripheral sites. It is ineffective against the central effects of organophosphate poisoning (e.g., respiratory center depression). **2. Analysis of Incorrect Options:** * **Obidoxime:** Like pralidoxime, it is a quaternary oxime. However, in the context of standard pharmacological teaching and competitive exams, **Pralidoxime** is the classic prototype cited for its inability to cross the BBB. (Note: While obidoxime also has poor CNS penetration, Pralidoxime is the most definitive answer in this MCQ format). * **Diacetyl monoxime (DAM):** Unlike pralidoxime, DAM is a **non-quaternary oxime**. It is lipid-soluble and **can cross the BBB**, allowing it to reactivate AChE within the CNS. * **Physostigmine:** This is a **tertiary amine** anticholinesterase. Being uncharged and lipid-soluble, it **crosses the BBB** easily. It is clinically used to treat central anticholinergic toxicity (e.g., Atropine overdose). **3. High-Yield Clinical Pearls for NEET-PG:** * **Tertiary vs. Quaternary:** Tertiary amines (Physostigmine, Atropine) cross the BBB; Quaternary amines (Neostigmine, Pralidoxime, Glycopyrrolate) do **not**. * **Oxime Rule:** Oximes must be administered before "aging" of the enzyme occurs. * **Drug of Choice:** Atropine is the physiological antagonist for OP poisoning, while Pralidoxime is the specific enzyme reactivator (antidote).

Question 126: Which of the following factors is affected by the bioavailability of a drug?

A. Half-life of the drug
B. Volume of distribution
C. Dose of the drug (Correct Answer)
D. pKa value

Explanation: **Explanation:** **Bioavailability ($F$)** is defined as the fraction of an administered dose of unchanged drug that reaches the systemic circulation. It is a key pharmacokinetic parameter used to calculate the appropriate dosage for different routes of administration. **Why the correct answer is right:** The relationship between dose and bioavailability is expressed by the formula: $$\text{Target Plasma Concentration} = \frac{\text{Bioavailability} \times \text{Dose}}{\text{Clearance}}$$ When a drug has low bioavailability (e.g., due to poor absorption or high first-pass metabolism), a **higher oral dose** must be administered to achieve the same therapeutic effect as an intravenous (IV) dose (where $F = 1$ or 100%). Therefore, the dose is directly adjusted based on the drug's bioavailability. **Why the incorrect options are wrong:** * **Half-life ($t_{1/2}$):** This is an intrinsic property determined by the drug's clearance and volume of distribution ($t_{1/2} = 0.693 \times Vd / CL$). It is independent of how much drug enters the body. * **Volume of Distribution ($Vd$):** This represents the theoretical space into which a drug distributes. It is a property of the drug's lipid solubility and protein binding, not its absorption fraction. * **pKa value:** This is a physicochemical property (dissociation constant) of the drug molecule that determines its ionization at a specific pH. While pKa *affects* bioavailability, it is not *affected by* it. **NEET-PG High-Yield Pearls:** * **IV Route:** By definition, the bioavailability of a drug administered intravenously is **100% ($F=1$)**. * **First-Pass Metabolism:** The most common reason for low oral bioavailability is extensive metabolism in the liver or gut wall before reaching systemic circulation (e.g., Nitroglycerin, Propranolol). * **Bioequivalence:** Two formulations of the same drug are bioequivalent if they show no significant difference in the rate and extent of absorption (AUC, $C_{max}$, and $T_{max}$).

Question 127: What is the active metabolite of carisoprodol?

A. Amphetamine
B. Meprobamate (Correct Answer)
C. Doxylamine
D. Dimethadione

Explanation: **Explanation:** **Carisoprodol** is a centrally acting skeletal muscle relaxant used for the relief of acute, painful musculoskeletal conditions. Its primary mechanism of action is mediated through its conversion into its active metabolite, **Meprobamate**. 1. **Why Meprobamate is correct:** Carisoprodol is a prodrug. Once ingested, it undergoes extensive hepatic metabolism via the cytochrome P450 enzyme **CYP2C19** to form Meprobamate. Meprobamate itself is an anxiolytic and sedative-hypnotic drug (historically used as a tranquilizer) that acts as a positive allosteric modulator at the **GABA-A receptor**. This metabolite accounts for much of the therapeutic muscle relaxant effect, as well as the drug's potential for abuse and sedation. 2. **Analysis of Incorrect Options:** * **Amphetamine:** This is a CNS stimulant. It is not a metabolite of carisoprodol; however, it is a metabolite of the anti-parkinsonian drug *Selegiline*. * **Doxylamine:** This is a first-generation antihistamine (H1 antagonist) with sedative properties, commonly used as a sleep aid. * **Dimethadione:** This is the active metabolite of the anticonvulsant *Trimethadione*. **NEET-PG High-Yield Pearls:** * **Abuse Potential:** Due to the Meprobamate metabolite, carisoprodol is classified as a Schedule IV controlled substance. It can cause withdrawal symptoms similar to benzodiazepines. * **Pharmacogenomics:** Patients who are "poor metabolizers" of **CYP2C19** will have higher serum levels of carisoprodol and lower levels of meprobamate, altering the drug's efficacy and toxicity profile. * **Other Muscle Relaxants to Remember:** * *Baclofen:* GABA-B agonist. * *Tizanidine:* Alpha-2 agonist. * *Dantrolene:* Acts directly on the Ryanodine receptor (RyR1) in the sarcoplasmic reticulum.

Question 128: What is the most important mechanism of drug transport across the cell membrane?

A. Filtration
B. Active transport
C. Passive diffusion (Correct Answer)
D. Facilitated diffusion

Explanation: **Explanation:** **Passive Diffusion** is the most important and common mechanism of drug transport, accounting for the absorption and distribution of approximately **90% of drugs**. 1. **Why Passive Diffusion is Correct:** Drugs move across the lipid bilayer along a concentration gradient (from higher to lower concentration) without the expenditure of energy (ATP). Since most drugs are small, lipid-soluble molecules, they can easily dissolve in the membrane's lipid matrix. This process is non-saturable and does not require a carrier protein, making it the most efficient and universal method for drug movement. 2. **Why Other Options are Incorrect:** * **Filtration:** This involves the passage of drugs through aqueous pores (aquaporins). It is limited to small, water-soluble molecules and is primarily significant in renal excretion (glomerular filtration), not general membrane transport. * **Active Transport:** This requires energy (ATP) and moves drugs *against* a concentration gradient. While vital for specific substances (e.g., levodopa, iron), it is limited by the availability of specific carriers and is saturable. * **Facilitated Diffusion:** Like passive diffusion, it follows a concentration gradient but requires a **carrier protein**. It is a specialized mechanism (e.g., glucose transport via GLUT4) and is not the primary route for most pharmacological agents. **High-Yield Clinical Pearls for NEET-PG:** * **Fick’s Law:** Governs passive diffusion; the rate of diffusion is directly proportional to the concentration gradient and lipid solubility. * **pH Partition Hypothesis:** Only the **un-ionized** (lipid-soluble) form of a drug crosses the membrane. Acidic drugs (e.g., Aspirin) are better absorbed in acidic environments (Stomach), while basic drugs (e.g., Atropine) are better absorbed in alkaline environments (Intestine). * **P-glycoprotein (P-gp):** An important efflux transporter (active transport) that pumps drugs out of cells, often contributing to multi-drug resistance in cancer.

Question 129: Therapeutic index is a measure of?

A. Efficacy
B. Adverse effects
C. Safety (Correct Answer)
D. Potency

Explanation: **Explanation:** **Therapeutic Index (TI)** is a quantitative measurement of the relative **safety** of a drug. It represents the ratio between the dose that produces toxicity and the dose that produces the desired therapeutic effect. Mathematically, it is expressed as: **TI = TD₅₀ / ED₅₀** (or LD₅₀ / ED₅₀ in animal studies) * **TD₅₀:** Dose that produces a toxic effect in 50% of the population. * **ED₅₀:** Dose that produces a therapeutic effect in 50% of the population. A **higher TI** indicates a wider margin of safety, meaning there is a large gap between the effective dose and the toxic dose (e.g., Penicillin, Paracetamol). Conversely, a **narrow TI** means the therapeutic and toxic doses are close, requiring frequent plasma drug monitoring (e.g., Lithium, Digoxin, Warfarin). **Why other options are incorrect:** * **Efficacy (A):** Refers to the maximum response ($E_{max}$) a drug can produce, regardless of dose. It is a measure of a drug's effectiveness, not safety. * **Adverse effects (B):** While TI relates to toxicity, it is a ratio comparing benefit to risk, not a measure of the side effects themselves. * **Potency (D):** Refers to the amount of drug (dose) required to produce an effect of a given intensity ($EC_{50}$). A more potent drug requires a smaller dose but is not necessarily safer. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs with Narrow Therapeutic Index (Mnemonic: Warning! Death Is Likely):** **W**arfarin, **D**igoxin, **I**nsulin, **L**ithium, **L**evothyroxine, **P**henytoin, **T**heophylline. * **Therapeutic Window:** The range of drug dosages which can treat disease effectively without having toxic effects. * **Certain Safety Factor:** Calculated as $LD_1 / ED_{99}$; it is a more stringent measure of safety than TI.

Question 130: Which of the nitrates can undergo first-pass metabolism?

A. Nitroglycerine
B. Pentaerythritol tetranitrate
C. Isosorbide dinitrate
D. All of the above (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. All of the above.** The underlying pharmacological concept here is **High First-Pass Metabolism (FPM)**. Organic nitrates are highly lipid-soluble drugs that are rapidly and extensively metabolized by the enzyme **glutathione-organic nitrate reductase** in the liver before reaching the systemic circulation. * **Nitroglycerine (Glyceryl Trinitrate - GTN):** It has a very high FPM (bioavailability <10%). This is why it is traditionally administered via the sublingual route to bypass the liver and provide rapid relief in angina. * **Isosorbide dinitrate (ISDN):** This also undergoes significant hepatic metabolism. While it can be given orally, its oral bioavailability is low (approx. 20-25%), and it is converted into active metabolites like Isosorbide-5-mononitrate. * **Pentaerythritol tetranitrate (PETN):** Like other organic nitrates, it is susceptible to hepatic degradation, necessitating higher oral doses to achieve therapeutic levels. **Why other options are "incorrect" as standalone choices:** Options A, B, and C are all individual nitrates that undergo first-pass metabolism. Since all three share this pharmacokinetic property, "All of the above" is the most accurate clinical answer. **High-Yield Clinical Pearls for NEET-PG:** 1. **Isosorbide-5-mononitrate:** Unlike the drugs listed above, this is the only nitrate that **does not** undergo significant first-pass metabolism (100% bioavailability). It is the preferred oral nitrate for chronic prophylaxis. 2. **Tachyphylaxis:** Continuous use of nitrates leads to "nitrate tolerance" due to the depletion of free sulfhydryl (-SH) groups. A "nitrate-free interval" of 8–12 hours is required daily to restore sensitivity. 3. **Monday Disease:** Workers in explosive factories (exposed to GTN) develop tolerance during the week but lose it over the weekend, leading to severe headaches (vasodilation) upon returning to work on Mondays.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free